Drug Search Results
More Filters [+]

WVE-N531

Alternative Names: wve-n531, wven531, wve n531
Latest Update: 2024-09-24
Latest Update Note: News Article

Product Description

WVE-N531 is Waves first exon skipping candidate, and the first candidate systemically administered by intravenous infusion, to utilize its novel PN backbone chemistry modifications.

Mechanisms of Action: Exon 53 Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Wave Life Sciences
Company Location: SINGAPORE U0 018936
Company CEO: Paul B. Bolno
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for WVE-N531

Countries in Clinic: Jordan, United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Muscular Dystrophy, Duchenne

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FORWARD-53

P2

Active, not recruiting

Muscular Dystrophy, Duchenne

2025-01-01

24%

Recent News Events